Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study

Jakob Dal¹, Ulla Feldt-Rasmussen², Marianne Andersen³, Lars Ø Kristensen⁴, Peter Laurberg⁵, Peter Jørgensen⁶, Lars Pedersen⁷, Olaf M Dekkers⁶,₇,₈, Henrik Toft Sørensen⁶ and Jens Otto L Jørgensen¹

¹Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark, ²Department of Endocrinology, National University Hospital, Copenhagen, Denmark, ³Department of Endocrinology, Odense University Hospital, Odense, Denmark, ⁴Department of Endocrinology, Herlev Hospital, Copenhagen, Denmark, ⁵Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark, ⁶Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus N, Denmark, ⁷Department of Medicine, Section of Endocrinology, and ⁸Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

†Deceased

Abstract

Design: Valid data on acromegaly incidence, complications and mortality are scarce. The Danish Health Care System enables nationwide studies with complete follow-up and linkage among health-related databases to assess acromegaly incidence, prevalence, complications and mortality in a population-based cohort study.

Method: All incident cases of acromegaly in Denmark (1991–2010) were identified from health registries and validated by chart review. We estimated the annual incidence rate of acromegaly per 10⁶ person-years (py) with 95% confidence intervals (95% CIs). For every patient, 10 persons were sampled from the general population as a comparison cohort. Cox regression and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were used.

Results: Mean age at diagnosis (48.7 years (CI: 95%: 47.2–50.1)) and annual incidence rate (3.8 cases/10⁶ persons (95% CI: 3.6–4.1)) among the 405 cases remained stable. The prevalence in 2010 was 85 cases/10⁶ persons. The patients were at increased risk of diabetes mellitus (HR: 4.0 (95% CI: 2.7–5.8)), heart failure (HR: 2.5 (95% CI: 1.4–4.5)), venous thromboembolism (HR: 2.3 (95% CI: 1.1–5.0)), sleep apnoea (HR: 11.7 (95% CI: 7.0–19.4)) and arthropathy (HR: 2.1 (95% CI: 1.6–2.6)). The complication risk was also increased before the diagnosis of acromegaly. Overall mortality risk was elevated (HR: 1.3 (95% CI: 1.0–1.7)) but uninfluenced by treatment modality.

Conclusion: (i) The incidence rate and age at diagnosis of acromegaly have been stable over decades, and the prevalence is higher than previously reported. (ii) The risk of complications is very high even before the diagnosis. (iii) Mortality risk remains elevated but uninfluenced by mode of treatment.

Introduction

Acromegaly is a rare condition predominantly caused by a growth hormone (GH)-secreting pituitary adenoma (1). Long-term presence of elevated GH and insulin-like growth factor I (IGF-I) levels is associated with complications such as heart failure, cerebrovascular disease, diabetes mellitus, sleep apnoea and arthropathy (1). These complications lead to increased mortality, particularly from cardiac disease and stroke (2, 3, 4). In addition, the pituitary adenoma and its treatment may contribute to morbidity and mortality (5).
For these reasons, several consensus statements emphasize the importance of rapid and permanent control of the disease in order to halt and reverse morbidity and mortality (6, 7). To optimize therapy and control of the disorder, data on the occurrence and outcome of acromegaly are essential. While data from several studies are published (2, 3), a series of issues remain unaddressed. First, accurate estimates of incidence and prevalence rates require population-based studies. Second, assessment of acromegaly-related complications and mortality necessitates long-term and complete follow-up and access to comparative data from the source population. The health care system in Denmark, with free access for patients to general practitioners and hospitals, provides unique opportunities to meet these methodological challenges. The unique civil registration number issued to all residents at birth or immigration permits complete follow-up, linkage among pertinent health-related databases, and provision of large comparison cohorts from the general population.

This study aimed to estimate incidence and prevalence of acromegaly in a population-based cohort study and to compare overall mortality and complications in acromegalic patients and a general population comparison cohort.

Subjects and methods

Source population and description of databases

The source population comprised the entire population of Denmark with approximately 7.2 million inhabitants during the 1991–2010 period. Data were obtained from the Danish National Patient Registry (DNPR), the Danish Civil Registration System (DCRS), the Danish Register of Causes of Death (DRCD) and systematic chart review of all patients diagnosed with acromegaly. The DNPR contains records of all hospital discharge diagnoses and surgical procedures since 1977 and all hospital outpatient specialist clinic and emergency department visits since 1995, coded according to the International Classification of Diseases (ICD), 8th and 10th revisions (8). The DCRS has kept electronic records of gender, age, birth date, residence, emigration date and vital status since 1968. The DRCD contains individual digitalized classification of causes of death in accordance with WHO’s rules and, since 1994, by ICD-10 codes (9). Accurate linkage of all registries at the individual level is possible using the unique central personal registry number assigned to each Danish resident at birth or immigration. The Danish National Health Service provides universal tax-supported health care, guaranteeing free access for patients to general practitioners and hospitals (10).

The study protocol was approved by the Danish National Board of Health (j.nr.3-3013-97/1) and the Danish Data Protection Agency.

Study population

The acromegaly cohort was identified from the DNPR using ICD-8 codes 25300 and 25301 and ICD-10 code DE220. These codes were recently validated in the DNRP (11). Furthermore, we reviewed each patient’s chart to confirm the diagnosis and to extract data on GH and IGF-I levels and the size of the pituitary adenoma.

The general population comparison cohort was drawn from the DCRS. For every acromegaly patient, 10 acromegaly-free persons in the general population were sampled from persons alive on the date of the acromegaly diagnosis (the ‘index date’), matched by age and sex. If persons in the comparison cohort developed acromegaly, follow-up was terminated and they started contributing person-time to the exposed cohort.

Laboratory test results and diagnostic imaging

Serum levels of GH and IGF-I at diagnosis were retrieved from patient charts; maximally suppressed GH levels during an oral glucose load (GHnadir) were retrieved, where available. Serum IGF-I concentrations were transformed into IGF-I standard deviation scores (IGF-SDSs) on the basis of age- and sex-specific IGF-I normal values. Pituitary adenoma size (maximal diameter) was identified from the diagnostic imaging report, where available.

Start of follow-up

Follow-up started on the date of the acromegaly diagnosis (date of diagnostic blood sample) and on the matched index date for the comparison cohort members. Follow-up was censored at time of death or emigration, or on 31 December 2012, whichever came first.

It is generally assumed that there is a 5–10 year delay in diagnosing acromegaly (1). This period, therefore, represents untreated exposure time to the disease. To ascertain the impact of the prediagnostic period on morbidity, we conducted a sensitivity analysis in which the follow-up period was confined to 3 years before diagnosis and ended for patients with acromegaly and
3 years before the index date for matched unexposed cohort members. By definition, risk estimates were based on nonfatal events during these prediagnostic years.

**Study endpoints**

We estimated and compared mortality rates in acromegaly patients and the general population cohort. We compared acromegalic patients and the matched population cohort regarding the first diagnosis of heart failure, acute myocardial infarction (AMI), stroke, diabetes mellitus, cancer, sleep apnoea, arthropathy, fracture and venous thromboembolism (VTE). For cause-specific mortality, we defined two groups: cancer-specific mortality, defined as death from any cancer, and cardiovascular mortality, defined as death from a cardiovascular cause. Any death not attributed to either cancer or cardiovascular disease was categorized as ‘other’.

Diagnoses in the DNPR were used for endpoint identification. Hospital discharge and outpatient visits are recorded in the DNPR with one primary diagnosis and one or more secondary diagnoses classified according to ICD-8 until the end of 1993 and ICD-10 thereafter. Relevant ICD codes are provided in Appendix 1, see section on Appendix given at the end of this article. For each event examined (heart failure, AMI, stroke, diabetes mellitus, cancer, sleep apnoea, arthropathy, fracture and VTE), we excluded acromegaly patients and comparison cohort members with a diagnosis of the given condition before start of follow-up.

**Statistical analysis**

We computed the annual incidence rate of acromegaly per 10⁶ person-years with 95% confidence intervals (95% CIs). Incidence rates were standardized to the age distribution of the Danish population in the year 2000. Prevalence was calculated per million inhabitants during 2010, the last year of study inclusion. As the prevalence estimation was based on prevalent cases and the study cohort included incident acromegaly patients since 1991, the numerator for prevalence estimation (n = 469) was larger than the number of included patients (n = 405).

For patients with acromegaly and persons in the population comparison cohort, we calculated the rate of heart failure, AMI, stroke, VTE, diabetes mellitus, hypertension, sleep apnoea, arthropathy, fracture, cancer, mortality and cause-specific mortality. The rates were expressed as the number of events per 1000 person-years. We used Kaplan–Meier analysis to construct survival curves and Cox regression for time-to-event analysis; hazard ratios (HRs) were computed with accompanying 95% CI. We also performed Cox regression to adjust for potential baseline imbalances, including smoking- and alcohol-related diagnoses, diabetes mellitus, cancer, obesity and hypertension. The risk of diabetes mellitus, cancer and hypertension was not adjusted for baseline imbalance in diabetes mellitus, cancer and hypertension respectively. The study design included adjustment for age and sex through matching. We conducted two stratified analyses: an analysis stratified by age at diagnosis (age <or= 50th percentile, e.g. 48.0 years) and a gender-specific analysis.
of complications. The association between GH and IGF-I and mortality was tested in an age- and sex-adjusted regression model based on logarithmically transformed GH and IGF-I values.

We performed additional analyses to assess the impact of different treatment strategies on mortality and morbidity. This was a within-cohort comparison, without use of a matched comparison cohort. As many treatments or treatment combinations are started after initial diagnosis, immortal time bias is relevant to consider (12). This bias occurs when exposure (e.g. treatment) starts after follow-up and the time until start of exposure is not accounted for appropriately. One way to circumvent immortal time bias is to start follow-up at a standardized point in time, and to determine exposure status at that time point. We, therefore, decided to categorize treatment after 2 years of initial diagnosis. Treatment was categorized as surgery only, medical therapy only (dopamine agonist, somatostatin analogues, pegvisomant or a combination), or combined surgical and medical therapies. In a multivariable model, we assessed the prognostic impact of radiotherapy. We combined acute events (AMI, VTE and stroke) and chronic conditions (sleep apnoea, HF, arthropathy and DM) to gain precision for this specific analysis.

**Results**

**Patient characteristics**

The study included 405 acromegaly patients and 4050 age- and gender-matched general population cohort members, of whom 47% were women. Mean age at diagnosis was 48.7 years (95% CI: 47.2–50.1), which was unchanged over time (Fig. 1A). Mean diagnostic GH
\[ \text{GH}_{\text{nadir}} \] and IGF-I-SDS results were 10.3 μg/L (95% CI: 8.8–12.1) and +5.2 SDS (95% CI: 4.9–5.4) respectively. Among acromegaly patients for whom details of the radiological assessment were available (\( n = 285 \)), 197 (69%) had a pituitary macroadenoma (≥10 mm) and 88 (31%) a microadenoma (<10 mm) (Table 1).

A weak inverse correlation was found between age at diagnosis and adenoma diameter (\( R^2 = 0.09, P < 0.01 \)). We recorded positive correlations between adenoma size and GH
\[ \text{GH}_{\text{nadir}} \] level (\( R^2 = 0.11, P < 0.01 \)) and between adenoma size and IGF-I-SDS level (\( R^2 = 0.08, P < 0.01 \)) respectively. Correspondingly, we observed that younger patients (<50th percentile) compared with older patients had larger adenomas (19.5 vs 10.0 mm, \( P < 0.01 \)), higher
Acromegaly incidence and prognosis

J Dal and others

Acromegaly incidence and prognosis

IGF-I-SDS levels (5.7 vs 5.0 SDS, \(P<0.00\)), and higher \(GH_{\text{nadir}}\) levels (14.0 vs 7.2 \(\mu\)g/L, \(P<0.01\)) at time of diagnosis. There was a similar sex distribution in the younger and older groups (data not shown). Male patients had higher \(GH_{\text{nadir}}\) levels (10.1 vs 7.9 \(\mu\)g/L, \(P=0.09\)) and higher IGF-I-SDS levels (5.5 vs 4.9, \(P<0.01\)) at diagnosis, although adenoma size (15.8 vs 15.0 mm, \(P=0.51\)) and age at diagnosis (48.6 vs 48.0 years, \(P=0.62\)) were comparable for males and females. Eighty percent were surgically treated, 56% of whom received additional medical treatment for acromegaly. The remaining 20% of the patient cohort received primary medical therapy. In the total cohort, 17% received radiation therapy.

Incidence and prevalence

The mean annual incidence rate of acromegaly was 3.8 (95% CI 3.7–4.0) cases/106 persons, remaining stable over calendar time. The point prevalence in 2010 was 85 cases/106 persons based on 469 acromegaly patients and a general population of 5,534,738 persons (Fig. 1B).

Mortality

During the follow-up period (mean follow-time 10.6 years), 73 patients with acromegaly died (18%). The mortality rate was higher in acromegaly patients (17.5/1000 person-years, 95% CI: 13.9–22.0) compared with the general population.

Table 2 Rates and hazard ratios with 95% confidence intervals (95% CIs) for the risk of selected comorbidity in patients with acromegaly, stratified by follow-up time.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Period (years before/after diagnosis)</th>
<th>Rate (95% CI) per 1000 person-years</th>
<th>Hazard ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Acromegaly cohort</td>
<td>Control cohort</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Age- and sex-adjusted model</td>
</tr>
<tr>
<td>Heart failure</td>
<td>0–3 years before</td>
<td>8.3 (4.5–15.5)</td>
<td>0.8 (0.4–1.5)</td>
</tr>
<tr>
<td></td>
<td>At diagnosis</td>
<td>4.7 (3.0–7.4)</td>
<td>2.0 (1.6–2.5)</td>
</tr>
<tr>
<td></td>
<td>0–1 year after</td>
<td>10.4 (3.9–27.7)</td>
<td>1.0 (0.7–3.3)</td>
</tr>
<tr>
<td></td>
<td>1–10 years after</td>
<td>5.5 (15.9–6.9)</td>
<td>2.0 (1.6–2.5)</td>
</tr>
<tr>
<td>AMI</td>
<td>0–3 years before</td>
<td>5.0 (2.3–11.2)</td>
<td>1.2 (0.7–2.0)</td>
</tr>
<tr>
<td></td>
<td>At diagnosis</td>
<td>3.2 (1.9–5.6)</td>
<td>2.9 (2.4–3.5)</td>
</tr>
<tr>
<td></td>
<td>0–1 year after</td>
<td>2.6 (0.4–18.4)</td>
<td>3.3 (1.9–5.7)</td>
</tr>
<tr>
<td></td>
<td>1–10 years after</td>
<td>3.3 (1.9–5.8)</td>
<td>2.9 (2.4–3.5)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>0–3 years before</td>
<td>30.3 (21.8–42.2)</td>
<td>1.9 (1.3–2.9)</td>
</tr>
<tr>
<td></td>
<td>At diagnosis</td>
<td>12.1 (9.0–16.4)</td>
<td>3.4 (2.9–4.1)</td>
</tr>
<tr>
<td></td>
<td>0–1 year after</td>
<td>37.7 (21.9–65.0)</td>
<td>2.6 (1.4–4.7)</td>
</tr>
<tr>
<td></td>
<td>1–10 years after</td>
<td>9.3 (6.5–13.4)</td>
<td>3.5 (3.0–4.2)</td>
</tr>
<tr>
<td>Stroke</td>
<td>0–3 years before</td>
<td>5.0 (2.2–11.0)</td>
<td>1.9 (1.3–2.9)</td>
</tr>
<tr>
<td></td>
<td>At diagnosis</td>
<td>4.0 (2.4–6.5)</td>
<td>3.2 (2.7–3.8)</td>
</tr>
<tr>
<td></td>
<td>0–1 year after</td>
<td>NE</td>
<td>2.5 (1.4–4.7)</td>
</tr>
<tr>
<td></td>
<td>1–10 years after</td>
<td>4.4 (2.7–7.2)</td>
<td>3.3 (2.8–3.9)</td>
</tr>
<tr>
<td></td>
<td>Arthropathy</td>
<td>16.5 (10.4–26.1)</td>
<td>8.2 (6.7–10.1)</td>
</tr>
<tr>
<td></td>
<td>0–3 years before</td>
<td>27.6 (22.5–34.0)</td>
<td>13.3 (12.2–14.5)</td>
</tr>
<tr>
<td></td>
<td>At diagnosis</td>
<td>11.5 (4.3–30.7)</td>
<td>13.5 (10.2–17.9)</td>
</tr>
<tr>
<td></td>
<td>0–1 year after</td>
<td>29.6 (23.9–36.6)</td>
<td>13.3 (12.1–14.6)</td>
</tr>
<tr>
<td>Sleep apnoea</td>
<td>0–3 years before</td>
<td>11.0 (6.4–19.0)</td>
<td>0.4 (0.2–1.0)</td>
</tr>
<tr>
<td></td>
<td>At diagnosis</td>
<td>9.8 (7.1–13.5)</td>
<td>0.9 (0.7–1.2)</td>
</tr>
<tr>
<td></td>
<td>0–1 year after</td>
<td>21.4 (10.7–42.7)</td>
<td>0.2 (0.0–1.8)</td>
</tr>
<tr>
<td></td>
<td>1–10 years after</td>
<td>8.5 (5.9–12.3)</td>
<td>1.0 (0.7–1.3)</td>
</tr>
<tr>
<td></td>
<td>VTE</td>
<td>1.7 (0.4–6.6)</td>
<td>1.0 (0.6–1.8)</td>
</tr>
<tr>
<td></td>
<td>0–3 years before</td>
<td>2.4 (1.3–4.5)</td>
<td>1.1 (0.8–1.4)</td>
</tr>
<tr>
<td></td>
<td>At diagnosis</td>
<td>NE</td>
<td>1.3 (0.5–3.0)</td>
</tr>
<tr>
<td></td>
<td>0–1 year after</td>
<td>NE</td>
<td>1.3 (0.5–3.0)</td>
</tr>
<tr>
<td>Fracture</td>
<td>0–3 years before</td>
<td>2.7 (1.4–5.0)</td>
<td>1.1 (0.8–1.4)</td>
</tr>
<tr>
<td></td>
<td>At diagnosis</td>
<td>7.8 (4.1–15.1)</td>
<td>6.4 (5.1–8.0)</td>
</tr>
<tr>
<td></td>
<td>0–1 year after</td>
<td>10.8 (4.0–28.7)</td>
<td>5.9 (3.9–9.0)</td>
</tr>
<tr>
<td></td>
<td>1–10 years after</td>
<td>6.6 (4.4–9.9)</td>
<td>8.6 (7.7–9.7)</td>
</tr>
</tbody>
</table>

NE, not estimated.

\(^a\)Model adjusted for age, sex, calendar time and baseline imbalances including hypertension, diabetes mellitus, cancer, smoke and alcoholism-related diseases.
population cohort (13.5/1000 person-years, 95% CI: 12.4–14.6), with an adjusted HR of 1.3 (95% CI: 1.0–1.7) (Fig. 2). The HR for mortality was higher in the first year after diagnosis (HR: 2.6 (95% CI: 1.2–5.6)) compared with subsequent years (HR: 1.2 (95% CI: 0.9–1.6)). Cancer-specific mortality was not clearly increased in acromegaly (HR: 1.1 (95% CI: 0.7–1.9)), whereas cardiovascular mortality was increased (HR: 1.6 (95% CI: 1.0–2.5)). The HR for any other causes was 1.4 (95% CI: 0.9–2.1).

When stratified by age, the HR was higher in the younger group (HR: 2.2 (95% CI: 1.1–4.3)) than in the older group (HR: 1.2 (95% CI: 0.9–1.6)), but similar in males and females. Mortality risk was not related to baseline IGF-I (P=0.93) or GH-nadir (P=0.61) at baseline (Appendix 2).

Cardiometabolic complications

Acromegaly patients were at increased risk of diabetes mellitus (HR: 4.0 (95% CI: 2.7–5.8)), heart failure (HR: 2.5 (95% CI: 1.4–4.5)) and VTE (HR: 2.3 (95% CI: 1.1–5.0)), while risk of stroke (HR: 1.1 (95% CI: 0.6–2.0)) and AMI (1.0 (95% CI: 0.5–1.9)) was unaffected. For heart failure and diabetes mellitus, the risks were most pronounced in the 3-year period before diagnosis. There was a subsequent decrease starting in the first year after diagnosis (Table 2). In addition, AMI risk was increased in the prediagnostic period (HR: 5.5 (95% CI: 1.8–16.7)). In the younger group, the risk of diabetes mellitus (HR: 4.8 (95% CI: 2.5–9.2)), heart failure (HR: 8.2 (95% CI: 2.8–24.5)) and VTE (HR: 4.4 (95% CI: 1.5–12.9)) remained increased, while in the older group, mainly the risk of diabetes mellitus was increased (HR: 3.2 (95% CI: 2.0–5.3; Table 3)). Of note, absolute risks for all events were higher in the older group. None of the VTE events occurred within 3 months after surgery. The overall risk for hypertension was increased, which largely was recorded in the first year after the diagnosis; however, the risk remained increased when excluding the first year after the diagnosis (HR: 8.8 (95% CI: 6.3–12.2)). The risk of hypertension also prevailed in the 3-year period before diagnosis (HR: 9.5 (95% CI: 5.9–15.2)) (Fig. 3, Tables 2 and 3).

Sleep apnoea, arthropathy and fracture risk

For acromegaly patients, the overall risks of sleep apnoea (HR: 11.7 (95% CI: 7.0–19.4)) and arthropathy (HR: 2.1 (95% CI: 1.6–2.6)) were increased, but not the overall risk of fractures (HR: 0.5 (95% CI: 0.5–1.2)). When the analysis was stratified by age at diagnosis, the older group had a higher risk of sleep apnoea (HR: 13.3 (95% CI: 5.9–30.0)) and arthropathy (HR: 2.5 (95% CI: 1.8–3.4)). However, these risks were also increased in the younger group. The risk of fractures was not elevated in either group. Higher levels of IGF-1 (HR: 1.38 (95% CI: 0.67–2.82)) and GH ((HR: 1.29 (95% CI: 1.06–1.56)) at baseline seemed associated with increased arthropathy risk (Appendix 2) (Fig. 3, Tables 2 and 3).

Cancer

In the acromegaly cohort, overall cancer risk tended to be increased (HR: 1.4 (95% CI: 0.9–2.2)); no increased risk for colorectal cancer (HR: 1.1 (95% CI: 0.4–2.9)), breast cancer (HR: 1.0 (95% CI: 0.4–2.8)) or lung cancer (HR: 0.9 (95% CI: 0.3–3.0)) was evident.

Mortality and morbidity outcome according to therapy

For the analyses based on treatment, we defined treatment (strategies) 2 years after initial diagnosis. Of all patients still in follow-up after 2 years (n=387), 171 patients were treated by surgery only, 102 by a combination of surgery and medication, and 62 by medication only. Long-term mortality risks were similar in the three groups, and no significant differences were found when comparing the three groups for acute cardiovascular events (AMI, VTE and stroke) or chronic conditions. In a multivariable model, radiotherapy...
was not clearly associated with mortality \( (P=0.6) \) or cardiovascular disease \( (0.2) \) (Appendix 3).

**Discussion**

This population-based cohort study was conducted to provide updated, accurate estimates regarding the epidemiology of acromegaly, including age at diagnosis, incidence and prevalence rates, and rates of complications and mortality. The strengths of our study include its population-based design with a general population comparison cohort and linkage among multiple health-related registries using a unique identifier.

We found an average annual incidence rate of acromegaly of approximately 4 cases/10^6, which was constant over calendar time. This estimate lies within the range previously reported, albeit in the upper part of the range (13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25). We estimated the point prevalence as 85 cases/10^6 persons in 2010, which is higher than most previous reports (19, 20, 21, 22, 23, 24, 25).

There is a theoretical basis for a true prevalence as high as 120 cases/10^6 persons, based on the estimated annual incidence rate of 3.8 cases/10^6, an average age at diagnosis of 48.3 years, and a life expectancy slightly below that of the general population (78 years). This theoretical prevalence is in line with two recent publications based on small cohorts (7–9 cases) (15, 18).

Interestingly, the age at diagnosis did not decline during the 20-year calendar period of our study. This, together with the constant incidence rate, seems to suggest that diagnostic awareness is not increasing and that there has been no major effect of novel and more sensitive diagnostic work-up on acromegaly detection.

Although neither adenoma size nor age at diagnosis differed by gender, diagnostic GH and IGF-I levels were higher among males. In accordance with this finding, data from Finland showed slightly higher basal GH levels in male patients (26), and a German study reported a higher random GH level in male patients, who were also younger at diagnosis (27). However, another study reported that for a given GH level, female patients with active acromegaly had lower serum IGF-I levels compared with males. This was partly attributed to the suppressive effect of oestrogen on hepatic IGF-I production (28), but this study mainly included patients with residual disease activity after surgery and radiation therapy (28). Collectively, the data suggest that biochemical disease activity at diagnosis is greater in male compared with female patients. This was not explained by age or adenoma size at time of diagnosis.

### Table 3

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Age &gt; 50 percentile</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality</td>
<td>5.2 (3.0–9.2)</td>
<td>2.2 (1.1–4.3)</td>
<td>0.5 (0.2–1.2)</td>
</tr>
<tr>
<td>Heart failure</td>
<td>2.2 (2.8–24.5)</td>
<td>1.9 (0.7–5.0)</td>
<td>0.8 (0.3–2.2)</td>
</tr>
<tr>
<td>AMI</td>
<td>3.1 (6.5–15.5)</td>
<td>1.0 (0.5–2.2)</td>
<td>2.0 (1.0–4.0)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>2.2 (1.0–5.0)</td>
<td>2.8 (1.5–6.5)</td>
<td>3.4 (1.5–7.5)</td>
</tr>
<tr>
<td>Stroke</td>
<td>2.2 (1.0–5.0)</td>
<td>6.9 (1.3–12.1)</td>
<td>3.1 (1.0–5.5)</td>
</tr>
<tr>
<td>Arteriovenous thrombosis</td>
<td>1.3 (0.6–2.7)</td>
<td>14.5 (12.6–27.2)</td>
<td>1.3 (0.6–2.7)</td>
</tr>
<tr>
<td>Arterial occlusion</td>
<td>1.7 (0.9–3.4)</td>
<td>7.0 (5.5–13.6)</td>
<td>8.9 (7.0–10.8)</td>
</tr>
<tr>
<td>VTE</td>
<td>2.2 (1.4–3.5)</td>
<td>2.7 (1.8–4.0)</td>
<td>3.6 (2.6–4.9)</td>
</tr>
<tr>
<td>Fracture</td>
<td>2.2 (1.4–3.5)</td>
<td>2.7 (1.8–4.0)</td>
<td>3.6 (2.6–4.9)</td>
</tr>
<tr>
<td>Rates (95% CI) per 1000 person-years</td>
<td><em>Model fully adjusted for age, sex, calendar time and baseline imbalances including hypertension, diabetes mellitus, cancer, smoke and alcoholism-related diseases.</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Rates 95% CI:**
We showed increased complications in acromegaly patients, supporting previously published data (19, 29). Because this risk was most pronounced during the first year after diagnosis, it is possible that detection bias (detecting diseases due to the fact that patients come to medical attention) may have contributed to this finding. In particular, we believe that hypertension is subject to detection bias. It should also be noted that a constellation of symptoms may lead to a diagnosis of acromegaly, and the other way around, in patients with acromegaly, clinicians will search for acromegaly-related complications.

Importantly, however, increased morbidity was also evident in the 3-year prediagnostic period, adding new support to observations that the prediagnostic phase of acromegaly is sizeable and contributes to morbidity (27, 30, 31, 32, 33). This phenomenon, and also the highest mortality risk in the first year after diagnosis, might point towards reduction in morbidity and mortality due to effective treatment.

Risk of arthropathy was highest during long-term follow-up, which may reflect the slow and progressive effects of GH and IGF-I on this condition (34). GH excess also has been linked to the development of hypercoagulation and venous thrombosis (35). In accordance with this, we recorded a slightly increased risk of VTE in our study. In contrast to previous studies (36), we did not observe an increased risk of stroke. One potential explanation could be the limited use of pituitary irradiation in Denmark (only 17% in this cohort), as this treatment has been linked to late onset cerebrovascular damage and hence increased risk of stroke (36).

Vertebral fractures have been reported to be common among patients with acromegaly (37), and the risk of osteoporotic fractures has been linked to hypogonadism (38). However, we found no increase in the risk of fractures among our patients. This lacking association could reflect that vertebral fracture are largely asymptomatic and under-diagnosed (37).

Whether acromegaly is associated with an increased risk of cancer remains controversial (39), but most epidemiological studies have reported an increased risk of colorectal cancer (5, 40). While we observed only an increased overall cancer risk (HR: 1.4), the confidence intervals preclude a definitive resolution of this dispute. To gain statistical power, it would be of great relevance to perform a study focusing on cancer risk with prolonged follow-up in combination with a meta-analysis of published data.

We observed an inverse association between age at diagnosis and adenoma size, as well as biochemical disease activity, which is in accordance with other studies (41, 42, 43). It has been suggested that the etiology and pathogenesis of acromegaly may differ according to age at diagnosis, with more aggressive disease in young patients (44). To explore this, we stratified the cohort according to age at diagnosis and compared the risk of selected complications. In general, we found a higher relative risk in the younger group, especially as regards heart failure, diabetes mellitus and VTE. However, absolute risks remained highest in the older group. In contrast, the relative risks of arthropathy and sleep apnoea were highest in the older group, suggesting that these complications develop slowly. Although males were exposed to higher prediagnostic hormone levels, this did not translate into an increased risk of complications. In fact, risks of heart failure and diabetes mellitus were higher in females.

Mortality in patients with acromegaly has been examined in several studies and meta-analyses. The data suggest that the increased mortality risk has declined in recent years, attributed to improved treatment (2, 3). In our cohort, the overall mortality risk was only slightly elevated and in agreement with the literature (2, 3). We recorded an increased mortality from cardiovascular disease but not from cancer, which agrees with a meta-analysis from 2008 (2), although recent surveys from single centres report increased cancer mortality (45) and low prevalence of cardiac disease (46) respectively. Moreover, in a subanalysis, we did not record a significant impact of a given treatment strategy on mortality risk, acute cardiovascular event or chronic complications. To minimize the risk of immortal time bias, we categorized treatment after 2 years of initial diagnosis, and we excluded the small number of patients receiving irradiation. These data should be interpreted with caution and do not allow conclusion regarding the optimal treatment. For instance, it is likely that patients receiving a combination of treatments represent therapeutic challenges as compared with patients receiving surgery alone, and it is also likely that patients only receiving medical treatment differ from surgery-alone patients as regards operability. Nevertheless, we consider it reassuring that the prognosis after medical treatment alone or in combination with surgery is comparable to surgery alone.

In conclusion, this population-based cohort study provided novel and robust estimates of the incidence rate and prevalence of acromegaly. The observation that both the incidence rate and the age at diagnosis remained stable during the follow-up period, despite improvements in
diagnostic tools, merits consideration. Our design allowed a thorough investigation of disease-related complications, which was prevalent before diagnosis and remained elevated throughout the follow-up period. We believe that our data have implications for proper allocation of health care resources and individual management of patients with acromegaly.

Appendix
This is linked to the online version of the paper at http://dx.doi.org/10.1530/EJE-16-0117.

Declaration of interest
J D has received lecture fees from IPSEN, Novartis and Pfizer. U F R has received unrestricted grants from Pfizer and lecture fees from IPSEN, Novartis and Pfizer. L Ø K is a member of an advisory board for Novartis. P L is on the advisory board, is a clinical investigator and is a teacher for Novartis. J O L J has received lecture fees from IPSEN, Novartis and Pfizer and served on advisory boards for Novartis and Pfizer. M A, L P, O M D and H T S have nothing to declare.

Funding
This study was supported by grants from Pfizer and IPSEN.

References
35 Erem C, Nuhoglu I, Kocak M, Yilmaz M, Sipahi ST, Ucuncu O & Ersoz HO. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI. *Endocrine* 2008 33 270–276. (doi:10.1007/s12020-008-9088-4)

Received 15 February 2016
Revised version received 25 April 2016
Accepted 26 May 2016